New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study

IF 4.6 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes & metabolism Pub Date : 2025-01-07 DOI:10.1016/j.diabet.2025.101605

Yun Kyung Cho , Sehee Kim , Myung Jin Kim , Woo Je Lee , Ye-Jee Kim , Chang Hee Jung

{"title":"New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident pancreatic cancer: A nationwide population-based cohort study","authors":"Yun Kyung Cho , Sehee Kim , Myung Jin Kim , Woo Je Lee , Ye-Jee Kim , Chang Hee Jung","doi":"10.1016/j.diabet.2025.101605","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>We aimed to investigate whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a decreased risk of gastrointestinal (GI) cancers in patients with type 2 diabetes (T2D) compared to other glucose lowering medications (oGLMs).</div></div><div><h3>Methods</h3><div>This active-comparator, new-user cohort study used the nationwide National Health Insurance Service database of the Republic of Korea from September 2014 to June 2020. From 79,423 new users of SGLT2is and 294,707 new users of oGLMs, we used a propensity score to match 59,954 from each of these two treatment groups. We calculated hazard ratios (HRs) and 95 % confidence intervals (CIs) for the incidence of GI cancers, encompassing stomach, colorectal, liver, and pancreatic cancers.</div></div><div><h3>Results</h3><div>During the observation period, there were 814 and 916 GI cancers, and 794 and 1,140 deaths in the SGLT2is and oGLMs treatment groups, respectively. The use of SGLT2is was associated with a statistically significant reduction in the incidence of GI cancers, with an adjusted HR of 0.90 (95 % CI: 0.82 to 0.99). However, only the incidence of pancreatic cancer was significantly lower in SGLT2is users compared to non-users, with an adjusted HR of 0.72 (95 % CI: 0.55 - 0.95). In the entire cohort, the multivariable-adjusted HR for pancreatic cancer was 0.70 (95 % CI: 0.56 to 0.88).</div></div><div><h3>Conclusion</h3><div>For T2D patients, SGLT2i use was associated with a diminished pancreatic cancer risk compared to oGLMs. Future studies should ascertain the potential protective effect of SGLT2is against pancreatic cancer.</div></div>","PeriodicalId":11334,"journal":{"name":"Diabetes & metabolism","volume":"51 2","pages":"Article 101605"},"PeriodicalIF":4.6000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1262363625000011","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

We aimed to investigate whether sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a decreased risk of gastrointestinal (GI) cancers in patients with type 2 diabetes (T2D) compared to other glucose lowering medications (oGLMs).

Methods

This active-comparator, new-user cohort study used the nationwide National Health Insurance Service database of the Republic of Korea from September 2014 to June 2020. From 79,423 new users of SGLT2is and 294,707 new users of oGLMs, we used a propensity score to match 59,954 from each of these two treatment groups. We calculated hazard ratios (HRs) and 95 % confidence intervals (CIs) for the incidence of GI cancers, encompassing stomach, colorectal, liver, and pancreatic cancers.

Results

During the observation period, there were 814 and 916 GI cancers, and 794 and 1,140 deaths in the SGLT2is and oGLMs treatment groups, respectively. The use of SGLT2is was associated with a statistically significant reduction in the incidence of GI cancers, with an adjusted HR of 0.90 (95 % CI: 0.82 to 0.99). However, only the incidence of pancreatic cancer was significantly lower in SGLT2is users compared to non-users, with an adjusted HR of 0.72 (95 % CI: 0.55 - 0.95). In the entire cohort, the multivariable-adjusted HR for pancreatic cancer was 0.70 (95 % CI: 0.56 to 0.88).

Conclusion

For T2D patients, SGLT2i use was associated with a diminished pancreatic cancer risk compared to oGLMs. Future studies should ascertain the potential protective effect of SGLT2is against pancreatic cancer.

查看原文本刊更多论文

钠-葡萄糖共转运蛋白2抑制剂的新使用者患胰腺癌的风险较低：一项基于全国人群的队列研究

目的：我们旨在研究与其他降糖药物（oglm）相比，钠-葡萄糖共转运蛋白-2抑制剂（SGLT2is）是否与2型糖尿病（T2D）患者胃肠道（GI）癌症风险降低相关。方法：本研究采用2014年9月至2020年6月韩国国民健康保险服务数据库，采用主动比较，新用户队列研究。从79,423名SGLT2is新用户和294,707名oGLMs新用户中，我们使用倾向评分来匹配这两个治疗组的59,954名新用户。我们计算了胃肠道癌症（包括胃癌、结直肠癌、肝癌和胰腺癌）发病率的风险比（hr）和95%置信区间（CIs）。结果：观察期内，SGLT2is治疗组和oGLMs治疗组分别有814例和916例胃肠道肿瘤，794例和1140例死亡。SGLT2is的使用与胃肠道癌症发病率的统计学显著降低相关，调整后的风险比为0.90 （95% CI: 0.82至0.99）。然而，与非SGLT2is使用者相比，只有SGLT2is使用者的胰腺癌发病率显著降低，调整后的HR为0.72 (95% CI: 0.55 - 0.95)， SGLT2is使用者的胰腺癌风险降低。在整个队列中，胰腺癌的多变量校正HR为0.70 （95% CI: 0.56 ~ 0.88）。结论：对于T2D患者，与oGLMs相比，SGLT2i的使用与胰腺癌风险降低相关。未来的研究应确定SGLT2is对胰腺癌的潜在保护作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & metabolism 医学-内分泌学与代谢

CiteScore

12.00

自引率

4.20%

发文量

审稿时长

13 days

期刊介绍： A high quality scientific journal with an international readership Official publication of the SFD, Diabetes & Metabolism, publishes high-quality papers by leading teams, forming a close link between hospital and research units. Diabetes & Metabolism is published in English language and is indexed in all major databases with its impact factor constantly progressing. Diabetes & Metabolism contains original articles, short reports and comprehensive reviews.